dc.contributor.author |
Valencia Ayala, Edward |
|
dc.contributor.author |
Rodrigues da Cunha, Gisele |
|
dc.contributor.author |
Araujo Azevedo, Maira |
|
dc.contributor.author |
Calderón Sánchez, Maritza Mercedes |
|
dc.contributor.author |
Jimenez, Juan |
|
dc.contributor.author |
Venuto, Ana Paula |
|
dc.contributor.author |
Gazzinelli, Ricardo |
|
dc.contributor.author |
Ynocente Lavalle, Raúl Jesus |
|
dc.contributor.author |
Vidal Riva, Angela Giovana |
|
dc.contributor.author |
Hincapie, Robert |
|
dc.contributor.author |
Finn, M. G. |
|
dc.contributor.author |
Marques, Alexandre F. |
|
dc.date.accessioned |
2020-07-14T00:02:36Z |
|
dc.date.available |
2020-07-14T00:02:36Z |
|
dc.date.issued |
2020 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/8355 |
|
dc.description.abstract |
The leading animal model of experimental Chagas disease, the mouse, plays a significant role in studies for vaccine development, diagnosis, and human therapies. Humans, along with Old World primates, alone among mammals, cannot make the terminal carbohydrate linkage of the α-Gal trisaccharide. It has been established that the anti-α-Gal immune response is likely to be a critical factor for protection against Trypanosoma cruzi (T. cruzi) infection in humans. However, the mice customarily employed for the study of T. cruzi infection naturally express the α-Gal epitope and therefore do not produce anti-α-Gal antibodies. Here, we used the C57BL/6 α-1,3-galactosyltransferase knockout (α-GalT-KO) mouse, which does not express the α-Gal epitope as a model for experimental Chagas disease. We found the anti-α-Gal IgG antibody response to an increase in α-GalT-KO mice infected with Arequipa and Colombiana strains of T. cruzi, leading to fewer parasite nests, lower parasitemia, and an increase of INF-γ, TNF-α, and IL-12 cytokines in the heart of α-GalT-KO mice compared with α-GalT-WT mice on days 60 and 120 postinfection. We therefore agree that the C57BL/6 α-GalT-KO mouse represents a useful model for initial testing of therapeutic and immunological approaches against different strains of T. cruzi. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
American Chemical Society |
|
dc.relation.ispartofseries |
ACS Infectious Diseases |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Chagas disease |
en_US |
dc.subject |
mouse model |
en_US |
dc.subject |
Trypanosoma cruzi |
en_US |
dc.subject |
α-Gal |
en_US |
dc.subject |
α-Gal antibodies |
en_US |
dc.subject |
α-Gal knockout mouse |
en_US |
dc.title |
C57BL/6 α-1,3-Galactosyltransferase knockout mouse as an animal model for experimental Chagas disease |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1021/acsinfecdis.0c00061 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.03.08 |
|
dc.relation.issn |
2373-8227 |
|